Washington Manual of Medical Therapeutics
Hepatocellular Carcinoma
To view the entire topic, please log in or purchase a subscription.
The Washington Manual of Medical Therapeutics helps you diagnose and treat hundreds of medical conditions. Consult clinical recommendations from a resource that has been trusted on the wards for 50+ years. Explore these free sample topics:
-- The first section of this topic is shown below --
Epidemiology and Etiology
An estimated 42,220 patients will be diagnosed with liver and intrahepatic bile duct tumors in 2018 in the United States. Risk factors include chronic viral hepatitis B or C, autoimmune hepatitis, nonalcoholic steatohepatitis, hemochromatosis, and cirrhosis. Most patients with hepatocellular carcinoma (HCC) have cirrhosis.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Epidemiology and Etiology
An estimated 42,220 patients will be diagnosed with liver and intrahepatic bile duct tumors in 2018 in the United States. Risk factors include chronic viral hepatitis B or C, autoimmune hepatitis, nonalcoholic steatohepatitis, hemochromatosis, and cirrhosis. Most patients with hepatocellular carcinoma (HCC) have cirrhosis.
There's more to see -- the rest of this entry is available only to subscribers.
